nuchal translucency

The new technique measures a fluid-filled area behind the neck, known as nuchal translucency.

Furthermore, the triple test may be combined with an ultrasound measurement of nuchal translucency.

The nuchal translucency test correctly finds Down syndrome in 64 to 70 out of 100 fetuses who have it.

Common procedures include amniocentesis, sonograms, nuchal translucency testing, or genetic screening.

Among those fetuses whose nuchal translucency exceeds the normal values, there is a relatively high risk of significant abnormality.

Measuring the thickness of fluid or 'nuchal translucency' helps to estimate the risk of Down's syndrome.

The levels of these chemicals, combined with the nuchal translucency measurement, are used to calculate the risk of the baby having Down's syndrome.

Nuchal translucency test.

The nuchal translucency test and the first-trimester blood tests are often done together in what is called the first-trimester screening.

For the nuchal translucency test, your doctor or an ultrasound technologist spreads a gel on your belly.

At the end of the second trimester, the nuchal translucency can no longer be seen and instead the nuchal fold is measured.

(This is an ultrasound of the fetus's neck [nuchal translucency] and a test of your blood.)

Increased fetal nuchal translucency (NT) is an indicator of increased risk of Down syndrome.

In fetuses with a normal number of chromosomes, a thicker nuchal translucency is associated with other fetal defects and genetic syndromes.

The ultrasound test, called a nuchal translucency test, involves measuring the fluid that accumulates in the back of the neck of a fetus, just under the skin.

The ultrasound can show the age of the baby and measure the thickness of the skin at the back of the baby's neck (nuchal translucency, or NT).

In addition to regular prenatal care, prenatal aneuploidy screening based on maternal age, nuchal translucency scan and biomarkers is appropriate.

Perhaps the most common such test uses a measurement of the nuchal translucency thickness ("NT-test", or "Nuchal Scan").

Screening for Down syndrome by a combination of maternal age and thickness of nuchal translucency in the fetus at 11-14 weeks of gestation was introduced in the 1990s.

The tests used depend on the stage of pregnancy at which a woman requests testing, but they all combine blood tests with a special type of ultrasound, known as a nuchal translucency scan.

Most important to the accuracy of this risk assessment is having the ultrasound exam done with the most modern equipment by a highly skilled sonographer who is experienced at measuring nuchal translucency.

The scan is obtained with the fetus in sagittal section and a neutral position of the fetal head (neither hyperflexed nor extended, either of which can influence the nuchal translucency thickness).

They received first-trimester nuchal translucency assessment and chorionicity determination, a midtrimester anatomical survey, and fetal echo followed by growth scans, amniotic fluid assessment, and Doppler studies every two weeks.

The translucent area measured (the nuchal translucency) is only useful to measure between 11 and 14 weeks of gestation, when the fetal lymphatic system is developing and the peripheral resistance of the placenta is high.

In vanishing twin pregnancies with a second gestational sac with a dead fetus, first trimester screening should be based solely on the maternal age and the nuchal translucency scan as biomarkers are significantly altered in these cases.